Screening for Cancer
Human genome research is creating new opportunities for discovery of noninvasive methods to detect and reduce the risk of cancer. As an example, strategies for early detection of colorectal cancer include colonoscopy, sigmoidoscopy, and barium enemas. However, these are invasive procedures, and have been limited by patient compliance issues.[11,12] Testing of stool samples for occult blood is a noninvasive method to screen for colorectal cancer; however, it has not been shown to be sensitive or specific enough for early detection. Furthermore, patients need to change their diet before testing is performed, or they must undergo multiple fecal occult blood tests to increase the sensitivity and specificity of the tests.
Noninvasive methods to detect colorectal tumors are being researched, and have the potential to reduce the morbidity and mortality associated with colorectal cancer. Traverso et al. sought to determine the efficacy of detecting APC mutations (adenomatous polyposis coli gene) in DNA from stool samples using a newly developed method called digital protein truncation. Using this technique, researchers hypothesized that they would be able to identify many different mutations involved in colon carcinogenesis in a sensitive and specific way. Stool samples were collected and analyzed from 74 patients; some of these patients had nonmetastatic colorectal cancer and some did not have neoplastic disease.
Results showed that 57% of the patients with neoplasia had identifiable APC mutations. No APC mutations were identified in the control group. The researchers concluded that APC mutations can be identified in DNA collected from a stool sample in patients with relatively early stage colorectal tumors. Their early feasibility study shows a new, noninvasive way to detect colorectal neoplasms, which has evolved to include more genes and is a clinically available test. Oncology nurses will be involved increasingly in this type of noninvasive cancer screening, and as noted in the Essentials of Genetic and Genomic Nursing, will be using new genetic- and genomic-based information and interventions to improve their patients' health outcomes.
In recognition of the importance of screening and prevention of common diseases, the Agency for Healthcare Research and Quality (AHRQ) created a Guide to Clinical Preventive Services. This includes the US Preventive Services Task Force (USPSTF) recommendations on screening; counseling; and preventive medication topics, with clinical considerations for each topic. The Guide provides healthcare practitioners including nurses and nurse practitioners with an authoritative source for making decisions about risk-management services.
Financial Disclosure: The authors have no signifi cant fi nancial interest
or other relationship with the manufacturers of any products or
providers of any service mentioned in this article.
1. US Department of Health and Human Services, Personalized Medicine Coalition: Personalized Medicine 101. Available at: www.personalizedmedicinecoalition.org/sciencepolicy/personalmed-101_overview.php. Accessed on December 22, 2009.
2. American Cancer Society: A Cancer Source Book for Nurses, 8th edition. Varricchio CG, Ades TB, Hinds PS, et al (eds). Sudbury, MA, Jones & Bartlett Publishers, 2004.
3. Consensus Panel on Genetic/Genomic Nursing Competencies: Essentials of Genetic and Genomic Nursing: Competencies, Curricula Guidelines, and Outcome Indicators, 2nd edition. Silver Spring, MD, American Nurses Association, 2009. Available at: www.genome.gov/Pages/Careers/HealthProfessionalEducation/geneticscompetency.pdf. Accessed on December 22, 2009.
4. National Human Genome Research Institute: All about the Human Genome Project. Available at: www.genome.gov/10001772. Accessed on December 22, 2009.
5. National Human Genome Research Institute: Frequently Asked Questions About Genetic and Genomic Science. Available at:, 2009.
6. Guttmacher AE, Collins FS: Genomic medicine—a primer. N Engl J Med 347(19):1512–1520, 2002.
7. National Library of Medicine: What Are Genome-Wide Association Studies? Available at: http://ghr.nlm.nih.gov/handbook/genomicresearch/gwastudies. Accessed on December 22, 2009.
8. National Cancer Institute: The Cancer Genome Atlas. Available at: http://cancergenome.nih.gov/. Accessed on December 22, 2009.
9. US Department of Health and Human Services: Personalized Healthcare Initiative. Available at: www.hhs.gov/myhealthcare/. Accessed on December 22, 2009.
10. Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069–1075, 2008. .
11. Imperiale TF, Wagner DR, Lin CY, et al: Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 20(343):169–174, 2002.
12. Traverso G, Shuber A, Olsson L, et al: Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 359(9304):403–404, 2002.
13. Agency for Healthcare Research and Quality: Guide to Clinical Preventive Services, 2008. Available at: www.ahrq.gov/Clinic/cps3dix.htm. Accessed on December 22, 2009.
14. Yoon PW, Scheuner MT, Khoury MJ: Research priorities for evaluating family history in the prevention of common chronic diseases. Am J Prev Med 24(2):128–135, 2003.
15. National Cancer Institute: What You Need to Know About Breast Cancer. Available at: www.cancer.gov/cancertopics/wyntk/breast. Accessed on December 22, 2009.
16. US Preventive Services Task Force: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Recommendation statement. Ann Intern Med 143(5):355–361, 2005.
17. US Surgeon General: My Family Health Portrait. Available at: https://familyhistory.hhs.gov/fhh-web/home.action. Accessed on July 14, 2009.
18. Korf B, Mikhail FM: Overview of genetic diagnosis in cancer. Curr Protoc Hum Genet 55:10.1.1–10.1.8, 2007.
19. National Human Genome Research Institute: Talking Glossary, 2009. Available at: www.genome.gov/Glossary/. Accessed on December 22, 2009.
20. Taub R, Kirsch I, Morton C, et al: Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 79(24):7837–7841, 1982.
21. Baker SG: Improving the biomarker pipeline to develop and evaluate cancer screening tests. J Natl Cancer Inst 101(16):1116–1119, 2009.
22. Waldman SA, Hyslop T, Schulz S, et al: Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA 301(7):745–752, 2009.
23. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25(33):5287–5312, 2007.
24. Budhu A, Jia HL, Forgues M, et al: Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47(3):897–907, 2008. Available at http://www3.cancer.gov/intra/LHC/Budhu-Hep2008.pdf. Accessed on December 28, 2009.
25. National Human Genome Research Institute: Frequently Asked Questions About Pharmacogenomics. Available at: http://www.genome.gov/27530645. Accessed on December 22, 2009.
26. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27(12):2091–2096, 2009.
27. HemOnc today: Cetuximab labeling revised for KRAS mutations. Available at www.hemonctoday.com/article.aspx?rid=41841. Accessed on December 22, 2009.
28. National Cancer Institute: Trastuzumab. Available at: http://www.cancer.gov/cancertopics/druginfo/trastuzumab. Accessed on December 22, 2009.
29. Yang JJ, Cheng C, Yang W, et al: Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301(4):393–403, 2009.
30. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336(20):1401–1408, 1997.
31. Rubenstein WS: Hereditary breast cancer in Jews. Fam Cancer 3(3-4):249–257, 2004.
32. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian Version 1/2009. http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf. Accessed on January 26, 2010.
33. Cykert S, Phifer N, Hanson C: Tamoxifen for breast cancer prevention: A framework for clinical decisions. Obstet Gynecol 104(3):433–442, 2004.
34. King MC, Wieand S, Hale K, et al: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286(18):2251–2256, 2001.
35. Narod SA, Brunet JS, Ghadirian P, et al: Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356(9245):1876–1881, 2000.
36. Gronwald J, Tung N, Foulkes WD, et al: Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer 118(9):2281–2284, 2006.
37. Genetic and Rare Diseases Information Center (GARD), 2009. Available at http://rarediseases.info.nih.gov/GARD/. Accessed on January 25, 2010.